Fresenius Medical Care AG & Co. (FMS)
| Market Cap | 23.88B |
| Revenue (ttm) | 17.86B |
| Net Income (ttm) | 1.16B |
| Shares Out | 585.78M |
| EPS (ttm) | 2.28 |
| PE Ratio | 17.91 |
| Forward PE | 17.54 |
| Dividend | $1.52 |
| Dividend Yield | 3.73% |
| Trading Day | July 23 |
| Last Price | $40.77 |
| Previous Close | $40.66 |
| Change ($) | 0.11 |
| Change (%) | 0.27% |
| Day's Open | 40.71 |
| Day's Range | 40.65 - 40.96 |
| Day's Volume | 293,725 |
| 52-Week Range | 33.16 - 44.85 |
Plenty of investors focus in on dividends, and dividend aristocrats, but if those investors only look in the U.S. they could be missing out. The post 15 European Dividend Aristocrats to Diversify Your P...
Fresenius Medical (FMS) company receives expedited approval from NMPA permitting the Xenios AG's console and patient kits for ECMO therapy in China.
Fresenius Medical (FMS) inaugurates new training center in Korea to help in the improvement of patient care by offering comprehensive education programs for healthcare professionals.
HONG KONG--(BUSINESS WIRE)-- #chronickidneydisease--Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, recently announced the grand openin...
Fresenius Medical's (FMS) first-quarter earnings benefit from organic growth in Health Care Products segment, and performance in Asia Pacific.
HONG KONG--(BUSINESS WIRE)-- #IND2021--Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced an international campaign that r...
DALLAS, March 9, 2021 /PRNewswire/ -- Kidney dialysis patients across East Texas may have failed to receive critical medical treatment due to communication failures at facilities owned by Fresenius Medi...
HONG KONG--(BUSINESS WIRE)-- #ChooseToChallenge--Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has today launched its Asia Pacific Wo...
Fresenius Medical's (FMS) fourth-quarter earnings benefit from strength in Health Care Products segment, and performance across EMEA and Asia Pacific.
Shares of Fresenius Medical Care (NYSE:FMS) rose 0.0% after the company reported Q4 results. Quarterly Results Earnings per share fell 50.00% year over year to $0.76, which missed the estimate of $0.77.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
Here are some dirt-cheap MedTech value stocks which are expected to provide long-term gains in 2021.
WALTHAM, Mass., Jan. 11, 2021 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for people with chronic kidney failure, announced today that the company's Fre...
Fresenius Medical Care might not be a ten-bagger in the next few years. Conversely, the stock currently offers a very good risk/reward ratio.
Fresenius (FMS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services. However, intense competition remains a woe.
Is Fresenius Medical Care (FMS) a great pick from the value investor's perspective right now? Read on to know more.
David Herro (Trades, Portfolio), a portfolio manager of the Oakmark International Fund, disclosed this week that the fund's top four trades during the third quarter included new positions in Fresenius M...
The German Dividend Aristocrats (GDA) have been updated - this is the 2020 version. There are 53 (-1) identified Dividend Aristocrats in Germany as of November 2020.
Fresenius Medical's (FMS) third-quarter earnings benefit from stable segmental performance.
Despite the correction, stocks - especially US stocks - are still trading at very high multiples and it is difficult to find bargains. Bayer and Fresenius are two German large-cap stocks that are tradin...
Fresenius Medical Care AG & Co. KGaA (FMS) CEO Robert Powell on Q3 2020 Results - Earnings Call Transcript
Fresenius delivered very solid results despite the pandemic. Importantly, all guidance was confirmed.
Fresenius Medical Care's Unexciting Capital Markets Day
Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services. However, intense competition remains a woe.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
FMS vs. SMLR: Which Stock Is the Better Value Option?
Let's grab these three stocks that have continued to show tremendous promise despite market volatility resulting from the coronavirus pandemic.
Fresenius Medical Care Asia Pacific responds to call for education in preparation of ultrapure dialysis fluid in developing economies
While searching for a suitable value investment option, investors are unlikely to consider PEG ratio among a number of other popular value metrics.
Here are some dirt-cheap MedTech value stocks which have been battered by the pandemic-led market meltdown and can be considered for long-term gains.
Let's grab these three stocks that have shown tremendous promise amid the coronavirus pandemic.
FMS vs. SMLR: Which Stock Is the Better Value Option?
Here are some MedTech growth stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.
There are some drawbacks to using the PEG ratio though. It does not consider the very common situation of changing growth rates.
Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
Fresenius Medical Care is the largest dialysis provider in the world.
Fresenius (FMS) could produce exceptional returns because of its solid growth attributes.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
FMS vs. SMLR: Which Stock Is the Better Value Option?
Even though profit is a company's goal, cash is its lifeblood for existence and a measure of resiliency.
Fresenius Medical's (FMS) second-quarter earnings benefit from strong segmental performance.
Fresenius (FMS) could produce exceptional returns because of its solid growth attributes.
Fresenius SE & Co. KGaA (FSNUF) Management on Q2 2020 Results - Earnings Call Transcript
Fresenius Medical Care AG & Co. KGaA (FMS) CEO Robert Powell on Q2 2020 Results - Earnings Call Transcript
Fresenius CFO: Business model strong despite pandemic's challenges
Fresenius CFO Rachel Empey discusses the impact of the coronavirus pandemic on the health-care company's second-quarter earnings.
About FMS
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage rena... [Read more...]
| Industry Medical Care Facilities | IPO Date Sep 19, 1996 |
| CEO Rice Powell | Employees 124,995 |
| Stock Exchange NYSE | Ticker Symbol FMS |
Financial Performance
In 2020, FMS's revenue was $17.86 billion, an increase of 2.19% compared to the previous year's $17.48 billion. Earnings were $1.16 billion, a decrease of -2.94%.
Analyst Forecasts
According to 6 analysts, the average rating for FMS stock is "Buy." The 12-month stock price forecast is 39.24, which is a decrease of -3.75% from the latest price.